Table 3.
Immunoglobulin phenotypes by group
| Controlsa | High-risk pedigree relativesa | |||||
|---|---|---|---|---|---|---|
| All | Cancer-free | All | Cancer-free | Solid tumor | B-cell lymphoid malignancyb | |
| n | 159 | 153 | 117 | 99 | 14 | 4 |
| κ + λ (mg/dL), median (95% range) | ||||||
| FLC | 3.04 (1.55–6.30) | 3.00 (1.54–6.33) | 2.62 (1.61–5.14) | 2.60 (1.59–4.75) | 2.91 | 3.94 |
| IgA | 210 (77–497) | 206 (77–497) | 207 (60–428) | 209 (62–391) | 184 | 100 |
| IgG | 1116 (682–1586) | 1116 (672–1592) | 1108 (613–1526) | 1113 (638–1531) | 1011 | 856 |
| IgM | 68 (22–220) | 68 (22–220) | 92 (33–286) | 93 (31–301) | 68 | 108 |
| κ/λ ratio, % abnormalc | ||||||
| FLC | 2 (1.3%) | 2 (1.3%) | 8 (6.8%) | 5 (5.1%) | 2 | 1 |
| IgA | 8 (5.0%) | 7 (4.6%) | 7 (6.0%) | 5 (5.1%) | 2 | 0 |
| IgG | 8 (5.0%) | 8 (5.3%) | 12 (10.3%) | 9 (9.1%) | 2 | 1 |
| IgM | 8 (5.0%) | 7 (4.6%) | 3 (2.6%) | 3 (3.4%) | 0 | 0 |
Controls were selected to not have any hematological maliganacy. Sampled relatives in high-risk CLL pedigrees could not have CLL or SLL. aStatus at time of sampling. bB-cell lymphoid malignancies do not include CLL; 95% range indicates the 2.5th–97.5th percentile range. cFLC ratio is used clinically and abnormality is based on its established diagnostic range (0.26–1.65), otherwise abnormality is based on the HLC ratio 95% reference ranges from the controls as follows: 0.84–1.91 for IgA(κ/λ); 1.02–2.87 for IgG(κ/λ); and 1.00–2.90 for IgM(κ/λ). Table entries that are bold and italic indicate those that are statistically different between at-risk relatives and controls